[Present status of therapy of acute leukemia].
D000906:Antibodies; D000970:Antineoplastic Agents / Q000009:adverse effects; D001215:Asparaginase / Q000627:therapeutic use; D003165:Complement System Proteins; D003520:Cyclophosphamide / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005347:Fibroblasts / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007372:Interferons; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007962:Leukocytes / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000906:Antibodies; D000970:Antineoplastic Agents; D014750:Vincristine; D003520:Cyclophosphamide; D003165:Complement System Proteins; D007372:Interferons; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin
Stato attuale della terapia delle leucemie acute.